- Home
- NBTX vs ACEL Comparison
NBTX vs ACEL Comparison
Compare NBTX & ACEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NBTX | ACEL |
|---|---|---|
| Founded | 2003 | 2009 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Services-Misc. Amusement & Recreation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 940.2M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | NBTX | ACEL |
|---|---|---|
| Price | $22.91 | $11.26 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $8.00 | ★ $14.50 |
| AVG Volume (30 Days) | 50.1K | ★ 375.4K |
| Earning Date | 09-30-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.50 |
| Revenue | $11,930,711.00 | ★ $1,307,029,000.00 |
| Revenue This Year | N/A | $9.83 |
| Revenue Next Year | $136.64 | $4.14 |
| P/E Ratio | ★ N/A | $22.57 |
| Revenue Growth | N/A | ★ 7.97 |
| 52 Week Low | $2.82 | $9.02 |
| 52 Week High | $30.35 | $13.28 |
Technical Indicators
Market Signals| Indicator | NBTX | ACEL |
|---|---|---|
| Relative Strength Index (RSI) | 57.57 | 70.39 |
| Support Level | $20.83 | $10.32 |
| Resistance Level | $23.77 | $10.64 |
| Average True Range (ATR) | 0.88 | 0.26 |
| MACD | 0.17 | 0.12 |
| Stochastic Oscillator | 77.16 | 100.00 |
Price Performance
Historical ComparisonAbout NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
About ACEL Accel Entertainment Inc.
Accel Entertainment Inc is a distributed gaming and local entertainment operator in the United States. It is engaged in the installation, maintenance, operation, and servicing of gaming terminals and related equipment, redemption devices that disburse winnings and contain automated teller machine (ATM) functionality, and amusement devices in authorized non-casino locations such as restaurants, bars, taverns, convenience stores, liquor stores, truck stops, and grocery stores. The Company also operates stand-alone ATMs in gaming and non-gaming locations. It generates revenue from Net gaming, Amusement, Manufacturing, ATM fees, and others.